Weis Holger 4

What Happened
Holger Weis, Chief Executive Officer of Alaunos Therapeutics, received an award/acquisition of 3,880 shares of common stock on June 30, 2026. The shares were issued at an effective price of $2.26 per share, with an aggregate value of $8,769. The filing lists the transaction as an award/grant (transaction code A) and the footnote states these shares were issued in lieu of net salary.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02.
• Transaction type: Award/Grant (Code A). Shares acquired: 3,880 at $2.26 each; total value $8,769.
• Footnote F1: Shares issued in lieu of net salary.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing timeliness: Form filed July 2, 2026; the report does not indicate a late filing.

Context
This was a compensation-related issuance (shares in lieu of salary), which is routine and not the same signal as an open-market purchase by an insider. For retail investors, compensation awards provide transparency about executive pay but should not be interpreted alone as a buy or sell recommendation.